Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

Tiziana Life Sciences announces positive results from studies using nasal anti-CD3 mAb in traumatic spinal cord injury: New York Saturday, January 25, 2025, 13:00 Hrs [IST] Tizian ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...